P/E at 32.9 vs Industry's 32.43: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Premium Reflects Market Nuance

The current P/E of 32.90 for Sun Pharmaceutical Industries Ltd is just above the industry average of 32.43, indicating investors are willing to pay a modest premium for the stock relative to its peers. This premium is not excessive but suggests some confidence in the company’s earnings quality or growth prospects compared to the broader Pharmaceuticals & Biotechnology sector. The sector itself is characterised by a mix of growth and regulatory challenges, which often leads to valuation disparities within its constituents. Sun Pharma’s premium valuation may reflect its large-cap status and established market presence, but it also raises the question of whether this premium is justified given recent performance trends — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns across multiple periods reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has declined by 3.83%, underperforming the Sensex’s modest fall of 0.64%. This underperformance over the longer term contrasts sharply with the three-month period, where the stock gained 4.13% while the Sensex fell 3.68%. This divergence suggests a recent shift in investor sentiment or company fundamentals that has not yet fully translated into longer-term gains.

Shorter-term returns also show mixed signals. The one-month return is negative at -5.53%, lagging the Sensex’s 5.85% gain, while the year-to-date performance is a mild decline of 2.36%, though still outperforming the Sensex’s sharper fall of 7.42%. The stock’s one-week gain of 1.65% trails the Sensex’s 2.67%, but the one-day performance is positive at 0.67%, slightly ahead of the Sensex’s 0.48%. This pattern indicates volatility and a lack of consistent directional momentum in the near term, raising the question of whether the recent three-month rally is sustainable or a short-lived rebound — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Bearish Technical Setup

From a technical perspective, Sun Pharmaceutical Industries Ltd is trading below all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning below short, medium, and long-term averages typically signals a bearish trend or at least a lack of sustained upward momentum. The stock’s recent gain after three consecutive days of decline suggests a short-term bounce, but the overall technical picture remains weak. This configuration often indicates that any rallies may face resistance near these moving averages, especially the 50-day and 200-day lines, which are closely watched by market participants.

Relative Performance vs Sensex: Mixed Outcomes

When compared to the Sensex, Sun Pharmaceutical Industries Ltd has shown a mixed relative performance. Over the last three years, the stock has delivered a robust 69.76% return, more than doubling the Sensex’s 32.25% gain. This outperformance extends over five years, with a 160.32% return versus the Sensex’s 65.38%. However, the 10-year return of 101.71% lags the Sensex’s 204.85%, indicating that the stock’s long-term growth has been more modest relative to the broader market. This pattern suggests that while the company has delivered strong medium-term gains, it has not kept pace with the broader market’s rally over the last decade.

Sector Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen limited result announcements recently, with only one stock declaring results so far. That stock reported positive outcomes, indicating some pockets of strength within the sector. However, the sector’s overall performance remains uneven, with regulatory pressures and competitive dynamics continuing to weigh on valuations. Sun Pharmaceutical Industries Ltd’s valuation and performance must be viewed within this broader sector backdrop, where selective winners coexist with ongoing challenges.

Rating Context: Previously Hold, Now Reassessed

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as Hold. The rating was updated on 23 Feb 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. This change comes amid the stock’s mixed performance and valuation premium relative to the industry. The reassessment considers multiple parameters, including the stock’s recent momentum, valuation metrics, and sector dynamics — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Complex Picture Emerges from the Data

The data on Sun Pharmaceutical Industries Ltd paints a nuanced picture. The stock trades at a slight premium to its industry peers, reflecting some confidence in its earnings profile despite recent underperformance over the past year. The divergence between short-term gains and longer-term weakness highlights shifting momentum, while the technical setup remains cautious with the stock below all major moving averages. Relative to the Sensex, the stock has outperformed over medium-term horizons but lagged over the decade. The sector’s mixed results and ongoing challenges add further complexity to the valuation and performance outlook. Taken together, these factors underscore the importance of a multi-dimensional analysis when considering Sun Pharmaceutical Industries Ltd — what is the current rating?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today